Drugs / YL201
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06898957 | May 2025 → Jun 2031 expected | small cell lung carcinoma | Amgen | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06394414 | Apr 2024 → Apr 2027 expected | neoplasm | MediLink Therapeutics (Suzhou) Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT07407933 | Mar 2026 → Nov 2028 expected | small cell lung carcinoma | MediLink Therapeutics (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07307053 | Jan 2026 → Jan 2029 expected | high grade malignant neoplasm, metastatic neoplasm | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07258979 | Nov 2025 → Feb 2028 expected | nasopharyngeal carcinoma | MediLink Therapeutics (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07208773 | Oct 2025 → Jan 2027 expected | non-small cell lung carcinoma, small cell lung carcinoma | MediLink Therapeutics (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06057922 | Sep 2023 → Oct 2026 expected | neoplasm | MediLink Therapeutics (Suzhou) Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05434234 | May 2022 → Apr 2027 expected | neoplasm | MediLink Therapeutics (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06241846 | Feb 2024 → Feb 2027 expected | prostate carcinoma | MediLink Therapeutics (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07487896 | Mar 2026 → Apr 2028 expected | esophageal squamous cell carcinoma | MediLink Therapeutics (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06629597 | Dec 2024 → Dec 2027 expected | nasopharyngeal carcinoma | MediLink Therapeutics (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06612151 | Dec 2024 → Dec 2027 expected | small cell lung carcinoma | MediLink Therapeutics (Suzhou) Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YL201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07487896 ↗ |
| Modality | Other / unclassified | “YL201, a novel B7H3-targeting ADC” PMID 40082695 ↗ Mar 2025 |
| Route | Intravenous | “YL201 intravenous (IV) infusion” NCT05434234 ↗ |
| Target | CD276 | “targets B7-H3 (CD276)” NCT07307053 ↗ |